MRI-Guided Biopsy of Recurrent Prostate Cancer After Radiotherapy

Recurrent Prostate Cancer Clinical Trial

Official title:

MRI - Guided Biopsy for Suspicion of Locally Recurrent Prostate Cancer After External Beam Radiotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00775866
• Other study ID #: UHN REB 05-0641-C
• Secondary ID: Proposal Number
• Status: Completed
• Phase: N/A
• First received: October 16, 2008
• Last updated: November 27, 2017
• Start date: October 2006
• Est. completion date: September 15, 2017

Study information

• Verified date: November 2017
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study we will test a new procedure to guide needle biopsies into the prostate gland based on MRI. This study will be conducted in patients who may have recurrence of their cancer in the prostate gland after radiation therapy in order to map out the location of the recurrence. Using this technique, we will be able to measure the accuracy of MR images in identifying the site of tumour recurrence.

Description:

This study involves the technical development and clinical testing of a novel technique for magnetic resonance imaging (MRI) guided prostate biopsy in a 1.5T horizontal bore scanner using a dedicated interventional table. We primarily hypothesize that the integration of diagnostic and interventional MRI enables needle biopsy targeting to foci of tumor recurrence after radiotherapy, and will enable a determination of the diagnostic accuracy of MRI in mapping sub-sites of tumor recurrence after radiotherapy. RELEVANCE TO PUBLIC HEALTH: Patients with recurrence of their prostate cancer after radiotherapy currently face difficult choices. Standard second line treatments target the entire prostate gland and are associated many side effects. This study will directly improve the detection, spatial delineation, and characterization of prostate cancer persistence after radiotherapy. If anatomic patterns of disease persistence are found across patients, radiation delivery techniques will be suitably modified, which may translate to improved cure rates. Importantly, this study will establish a procedural platform for MRI-guidance of minimally invasive local salvage therapies. By precisely focusing salvage therapy to sites of tumor persistence within the prostate gland, side effects may be reduced in the future.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 82
• Est. completion date: September 15, 2017
• Est. primary completion date: May 2015
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Biochemical failure > 18 months after definitive external beam radiotherapy (ASTRO definition - revised version 2006: rise by 2 ng/mL or more above the nadir PSA)

• PSA <20 prior to initial course of external beam radiotherapy

• PSADT >3 months at failure

• Age = 18 years

• ECOG performance status 0 or 1 with >10 year life expectancy

• Fit for local anaesthesia

• Informed consent:

Exclusion Criteria:

• Contraindications to MRI

• Severe claustrophobia

• Bleeding diathesis and anti-coagulative therapy that cannot be temporarily ceased precluding brachytherapy

• Previous brachytherapy

• Active hormonal therapy

• Radiologic evidence of LN or distant metastases

• Other urinary or medical conditions deemed by the PI or associates to make the patient ineligible for MRI-guided prostate biopsy.

• Contraindications to endorectal coil, surgically absent rectum, severe hemorrhoids or previous colorectal surgery

• Contraindications to conscious sedation

• Contraindication to IV Gadolinium administration

• latex allergy

Related Conditions & MeSH terms

• Prostatic Neoplasms
• Recurrent Prostate Cancer

Intervention

Procedure:
• MRI-Guided Biopsy
Technical development and clinical testing of a novel technique for magnetic resonance imaging (MRI) guided prostate biopsy in a 1.5T horizontal bore scanner using a dedicated interventional table.

Locations

Country	Name	City	State
Canada	University Health Network	Toronto	Ontario

Sponsors (3)

Lead Sponsor	Collaborator
University Health Network, Toronto	Princess Margaret Hospital, Canada, U.S. Army Medical Research and Materiel Command

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Ménard C, Iupati D, Publicover J, Lee J, Abed J, O'Leary G, Simeonov A, Foltz WD, Milosevic M, Catton C, Morton G, Bristow R, Bayley A, Atenafu EG, Evans AJ, Jaffray DA, Chung P, Brock KK, Haider MA. MR-guided prostate biopsy for planning of focal salvage after radiation therapy. Radiology. 2015 Jan;274(1):181-91. doi: 10.1148/radiol.14122681. Epub 2014 Sep 8. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint is a preliminary estimate of the diagnostic accuracy of MRI in identifying sites of recurrent tumor after radiotherapy for prostate cancer.		at the end of the evaluation phase